BioXcel Therapeutics Analyst Ratings
BioXcel Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/26/2023 | -16.48% | Goldman Sachs | $16 → $26 | Maintains | Neutral |
| 01/03/2023 | 134.5% | HC Wainwright & Co. | $85 → $73 | Maintains | Buy |
| 12/01/2022 | -48.6% | Goldman Sachs | → $16 | Upgrades | Sell → Neutral |
| 11/16/2022 | -42.18% | Mizuho | $19 → $18 | Maintains | Buy |
| 11/11/2022 | -19.69% | Guggenheim | $28 → $25 | Maintains | Buy |
| 11/11/2022 | 144.14% | Canaccord Genuity | $75 → $76 | Maintains | Buy |
| 11/11/2022 | -42.18% | Mizuho | $19 → $18 | Maintains | Buy |
| 08/24/2022 | 173.05% | HC Wainwright & Co. | $110 → $85 | Maintains | Buy |
| 07/07/2022 | -38.97% | Mizuho | → $19 | Initiates Coverage On | → Buy |
| 05/23/2022 | 253.36% | HC Wainwright & Co. | $134 → $110 | Maintains | Buy |
| 04/14/2022 | 330.45% | HC Wainwright & Co. | $130 → $134 | Maintains | Buy |
| 03/14/2022 | 317.6% | HC Wainwright & Co. | $140 → $130 | Maintains | Buy |
| 02/16/2022 | -19.69% | UBS | $88 → $25 | Maintains | Buy |
| 11/15/2021 | -22.9% | Goldman Sachs | $55 → $24 | Downgrades | Buy → Sell |
| 06/28/2021 | 349.73% | HC Wainwright & Co. | $176 → $140 | Maintains | Buy |
| 06/23/2021 | 301.54% | Truist Securities | $128 → $125 | Maintains | Buy |
| 06/01/2021 | 465.37% | HC Wainwright & Co. | $170 → $176 | Maintains | Buy |
| 05/11/2021 | 446.1% | HC Wainwright & Co. | $175 → $170 | Maintains | Buy |
| 04/09/2021 | 140.93% | Berenberg | → $75 | Initiates Coverage On | → Buy |
| 04/01/2021 | 205.17% | Canaccord Genuity | $110 → $95 | Maintains | Buy |
| 04/01/2021 | 307.97% | Truist Securities | $150 → $127 | Maintains | Buy |
| 04/01/2021 | 462.16% | HC Wainwright & Co. | $185 → $175 | Maintains | Buy |
| 02/01/2021 | 218.02% | UBS | → $99 | Initiates Coverage On | → Buy |
| 01/06/2021 | 494.28% | HC Wainwright & Co. | $175 → $185 | Maintains | Buy |
| 11/18/2020 | 253.36% | Canaccord Genuity | $108 → $110 | Maintains | Buy |
| 09/02/2020 | 163.41% | Jefferies | → $82 | Initiates Coverage On | → Buy |
| 08/17/2020 | 205.17% | BMO Capital | $104 → $95 | Maintains | Outperform |
| 08/17/2020 | 462.16% | HC Wainwright & Co. | $200 → $175 | Maintains | Buy |
| 07/21/2020 | 285.48% | Canaccord Genuity | $71 → $120 | Maintains | Buy |
| 07/20/2020 | 542.47% | HC Wainwright & Co. | $120 → $200 | Maintains | Buy |
| 07/13/2020 | 102.38% | B of A Securities | $53 → $63 | Reiterates | → Buy |
| 07/08/2020 | 285.48% | HC Wainwright & Co. | $95 → $120 | Reiterates | → Buy |
| 06/04/2020 | 224.45% | Guggenheim | → $101 | Initiates Coverage On | → Buy |
| 04/01/2020 | 44.56% | B of A Securities | → $45 | Initiates Coverage On | → Buy |
| 02/26/2020 | 205.17% | HC Wainwright & Co. | $30 → $95 | Reiterates | → Buy |
| 02/21/2020 | 118.44% | Canaccord Genuity | $27 → $68 | Maintains | Buy |
| 02/14/2020 | 381.85% | SunTrust Robinson Humphrey | $24 → $150 | Maintains | Buy |
| 01/08/2020 | -3.63% | HC Wainwright & Co. | $25 → $30 | Maintains | Buy |
| 11/12/2019 | -22.9% | SunTrust Robinson Humphrey | → $24 | Initiates Coverage On | → Buy |
| 05/03/2018 | -19.69% | HC Wainwright & Co. | → $25 | Initiates Coverage On | → Buy |
| 04/02/2018 | -51.81% | Barclays | → $15 | Initiates Coverage On | → Overweight |
| 04/02/2018 | -42.18% | UBS | → $18 | Initiates Coverage On | → Buy |
| 04/02/2018 | -26.12% | BMO Capital | → $23 | Initiates Coverage On | → Outperform |
| 04/02/2018 | -32.54% | Canaccord Genuity | → $21 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 01/26/2023 | -16.48% | 高盛 | $16 → $26 | 維護 | 中性 |
| 01/03/2023 | 134.5% | HC Wainwright公司 | $85 → $73 | 維護 | 買 |
| 12/01/2022 | -48.6% | 高盛 | → $16 | 升級 | 賣出→中性 |
| 11/16/2022 | -42.18% | 瑞穗 | $19 → $18 | 維護 | 買 |
| 11/11/2022 | -19.69% | 古根海姆 | $28 → $25 | 維護 | 買 |
| 11/11/2022 | 144.14% | 卡納科特·格納奇 | $75 → $76 | 維護 | 買 |
| 11/11/2022 | -42.18% | 瑞穗 | $19 → $18 | 維護 | 買 |
| 08/24/2022 | 173.05% | HC Wainwright公司 | $110 → $85 | 維護 | 買 |
| 07/07/2022 | -38.97% | 瑞穗 | → $19 | 開始承保 | →購買 |
| 05/23/2022 | 253.36% | HC Wainwright公司 | $134 → $110 | 維護 | 買 |
| 04/14/2022 | 330.45% | HC Wainwright公司 | $130 → $134 | 維護 | 買 |
| 03/14/2022 | 317.6% | HC Wainwright公司 | $140 → $130 | 維護 | 買 |
| 02/16/2022 | -19.69% | 瑞銀集團 | $88 → $25 | 維護 | 買 |
| 11/15/2021 | -22.9% | 高盛 | $55 → $24 | 評級下調 | Buy→Sell |
| 06/28/2021 | 349.73% | HC Wainwright公司 | $176 → $140 | 維護 | 買 |
| 06/23/2021 | 301.54% | Truist證券 | $128 → $125 | 維護 | 買 |
| 06/01/2021 | 465.37% | HC Wainwright公司 | $170 → $176 | 維護 | 買 |
| 05/11/2021 | 446.1% | HC Wainwright公司 | $175 → $170 | 維護 | 買 |
| 04/09/2021 | 140.93% | 貝倫伯格 | → $75 | 開始承保 | →購買 |
| 04/01/2021 | 205.17% | 卡納科特·格納奇 | $110 → $95 | 維護 | 買 |
| 04/01/2021 | 307.97% | Truist證券 | $150 → $127 | 維護 | 買 |
| 04/01/2021 | 462.16% | HC Wainwright公司 | $185 → $175 | 維護 | 買 |
| 02/01/2021 | 218.02% | 瑞銀集團 | → $99 | 開始承保 | →購買 |
| 01/06/2021 | 494.28% | HC Wainwright公司 | $175 → $185 | 維護 | 買 |
| 11/18/2020 | 253.36% | 卡納科特·格納奇 | $108 → $110 | 維護 | 買 |
| 09/02/2020 | 163.41% | 傑富瑞 | → $82 | 開始承保 | →購買 |
| 08/17/2020 | 205.17% | 蒙特利爾銀行資本 | $104 → $95 | 維護 | 跑贏大盤 |
| 08/17/2020 | 462.16% | HC Wainwright公司 | $200 → $175 | 維護 | 買 |
| 07/21/2020 | 285.48% | 卡納科特·格納奇 | $71 → $120 | 維護 | 買 |
| 07/20/2020 | 542.47% | HC Wainwright公司 | $120 → $200 | 維護 | 買 |
| 07/13/2020 | 102.38% | B of A證券 | $53 → $63 | 重申 | →購買 |
| 07/08/2020 | 285.48% | HC Wainwright公司 | $95 → $120 | 重申 | →購買 |
| 06/04/2020 | 224.45% | 古根海姆 | → $101 | 開始承保 | →購買 |
| 04/01/2020 | 44.56% | B of A證券 | → $45 | 開始承保 | →購買 |
| 02/26/2020 | 205.17% | HC Wainwright公司 | $30 → $95 | 重申 | →購買 |
| 02/21/2020 | 118.44% | 卡納科特·格納奇 | $27 → $68 | 維護 | 買 |
| 02/14/2020 | 381.85% | SunTrust Robinson Humphrey | $24 → $150 | 維護 | 買 |
| 01/08/2020 | -3.63% | HC Wainwright公司 | $25 → $30 | 維護 | 買 |
| 11/12/2019 | -22.9% | SunTrust Robinson Humphrey | → $24 | 開始承保 | →購買 |
| 05/03/2018 | -19.69% | HC Wainwright公司 | → $25 | 開始承保 | →購買 |
| 04/02/2018 | -51.81% | 巴克萊 | → $15 | 開始承保 | →超重 |
| 04/02/2018 | -42.18% | 瑞銀集團 | → $18 | 開始承保 | →購買 |
| 04/02/2018 | -26.12% | 蒙特利爾銀行資本 | → $23 | 開始承保 | →跑贏大盤 |
| 04/02/2018 | -32.54% | 卡納科特·格納奇 | → $21 | 開始承保 | →購買 |
What is the target price for BioXcel Therapeutics (BTAI)?
BioXcel治療公司(BTAI)的目標價格是多少？
The latest price target for BioXcel Therapeutics (NASDAQ: BTAI) was reported by Goldman Sachs on January 26, 2023. The analyst firm set a price target for $26.00 expecting BTAI to fall to within 12 months (a possible -16.48% downside). 13 analyst firms have reported ratings in the last year.
高盛於2023年1月26日報道了BioXcel治療公司(納斯達克：BTAI)的最新目標價。這家分析公司將目標價定為26.00美元，預計BTAI將在12個月內降至(可能下跌16.48%)。過去一年，有13家分析公司公佈了評級。
What is the most recent analyst rating for BioXcel Therapeutics (BTAI)?
BioXcel治療公司(BTAI)的最新分析師評級是什麼？
The latest analyst rating for BioXcel Therapeutics (NASDAQ: BTAI) was provided by Goldman Sachs, and BioXcel Therapeutics maintained their neutral rating.
高盛提供了對BioXcel治療公司(納斯達克代碼：BTAI)的最新分析師評級，BioXcel治療公司維持其中性評級。
When is the next analyst rating going to be posted or updated for BioXcel Therapeutics (BTAI)?
BioXcel治療公司(BTAI)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of BioXcel Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for BioXcel Therapeutics was filed on January 26, 2023 so you should expect the next rating to be made available sometime around January 26, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閲公共財務報表，與BioXcel治療公司的高管和客户交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。BioXcel治療公司的上一次評級是在2023年1月26日提交的，所以你應該預計下一次評級將在2024年1月26日左右的某個時候提供。
Is the Analyst Rating BioXcel Therapeutics (BTAI) correct?
分析師對BioXcel治療公司(BTAI)的評級正確嗎？
While ratings are subjective and will change, the latest BioXcel Therapeutics (BTAI) rating was a maintained with a price target of $16.00 to $26.00. The current price BioXcel Therapeutics (BTAI) is trading at is $31.13, which is out of the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的BioXcel治療公司(BTAI)評級保持不變，目標價在16.00美元至26.00美元之間。BioXcel治療公司(BTAI)目前的交易價格為31.13美元，超出了分析師的預測範圍。